Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Blood-brain Barrier

The Blood-brain Barrier

Neurogenesis and Regeneration of Nervous Tissue

Neurogenesis and Regeneration of Nervous Tissue

In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Molecular and Structural Characterization Reveals Divergent Extracellular Vesicle Profiles Between Wild Type and Alzheimer's Disease Cerebrocortical Organoids.

bioRxiv : the preprint server for biology·2026

Same author

Redox regulation of neuroinflammatory pathways contributes to damage in Alzheimer's disease brain.

Cell chemical biology·2026

Same author

Aberrant Protein S-Nitrosylation Mimics the Effect of Rare Genetic Mutations in Neurodegenerative Diseases.

Journal of neurochemistry·2026

Same author

Autophagy Activators Normalize Aberrant Tau Proteostasis and Rescue Synapses in Human Familial Alzheimer's Disease iPSC-Derived Cortical Organoids.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

The transcriptional and cellular landscape of cognitive resilience to Alzheimer's disease.

Frontiers in molecular neuroscience·2025

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

Published on: January 4, 2015

Pathologically activated therapeutics for neuroprotection.

Stuart A Lipton¹

¹Burnham Institute for Medical Research, The Salk Institute for Biological Studies, The Scripps Research Institute, and the University of California at San Diego 10901 North Torrey Pines Road, La Jolla, California 29,037, USA. slipton@burnham.org

Nature Reviews. Neuroscience

|September 21, 2007

Summary

This summary is machine-generated.

Developing effective and well-tolerated neuroprotective drugs is crucial for treating neurodegenerative diseases. Strategies focus on activating drugs via pathological states, exemplified by memantine, an N-methyl-D-aspartate receptor antagonist.

More Related Videos

Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging

Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging

Published on: April 6, 2014

Strategies for Study of Neuroprotection from Cold-preconditioning

Strategies for Study of Neuroprotection from Cold-preconditioning

Published on: September 2, 2010

Related Experiment Videos

Last Updated: Jul 11, 2026

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

Published on: January 4, 2015

Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging

Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging

Published on: April 6, 2014

Strategies for Study of Neuroprotection from Cold-preconditioning

Strategies for Study of Neuroprotection from Cold-preconditioning

Published on: September 2, 2010

Area of Science:

Neuroscience
Pharmacology
Drug Development

Background:

Many neuroprotective drug candidates fail clinical trials due to poor human tolerability.
Existing treatments for neurodegenerative diseases often have significant side effects.
There is a critical need for effective and safe therapeutic strategies.

Purpose of the Study:

To outline strategies for developing neuroprotective therapeutics that are both effective and well-tolerated.
To introduce a novel drug development principle based on pathological state activation.
To highlight the potential of targeted drug activation in improving therapeutic outcomes.

Main Methods:

Describing a series of strategic approaches for neuroprotective drug development.
Focusing on the principle of activating drugs in response to specific pathological conditions.
Reviewing existing successful applications of this principle in drug discovery.

Main Results:

The proposed strategies aim to enhance drug efficacy while minimizing off-target effects and toxicity.
The principle of pathological state-activated drug release offers a promising avenue for safer neuroprotection.
Memantine, an N-methyl-D-aspartate (NMDA)-type and glutamate receptor antagonist, serves as a successful example of this approach.

Conclusions:

Developing drugs activated by pathological states can lead to more effective and better-tolerated neuroprotective therapies.
This strategy holds significant promise for overcoming the challenges in treating neurodegenerative diseases.
Further research into pathological state-activated therapeutics could revolutionize treatment paradigms.